A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome

Exclusion Criteria

• •1. Absence of detectable mitochondria mutation or deletion.
• •2. Patient or patient's mother have a positive test for microbiologic
• •3. Patient is unable to undergo leukapheresis.
• •4. Patient suffers from chronic severe infection, malignant disease or any other disease or condition that may risk the patient or interfere with the ability to interpret the study results.
• •5. Patient has been treated previously with any cell or gene therapy.
• •6. Patient has participated in another clinical treatment trial or received other experimental medications outside of a clinical trial within 1 month prior to start of this study.